+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Coronavirus Drug Discovery. Volume 3: Druggable Targets and In Silico Update. Drug Discovery Update

  • Book
  • July 2022
  • Elsevier Science and Technology
  • ID: 5562082

Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.

In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

PART 1: DRUGGABLE TARGETS AND SIGNALING PATHWAYS  1. SARS-CoV-2 genome sequencing and promising druggable targets 2. Signaling pathways implicated in SARS-CoV2 infection 3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease 4. Potential Drugs in SARS-CoV-2 Treatment: Key Features and Mechanisms of Actions

PART 2: COMPUTATIONAL APPROACHES 5. Application of computational tools for coronavirus drug discovery 6. In silico Approaches in Drug Discovery for SARS-CoV-2 7. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: Ligand-protein interaction studies 8. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19  9. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2  10. In-silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and non-structural proteins  11. In silico Evaluation of Anti-SARS-CoV-2 Activity of Punica granatum L. Phytochemicals 12. In silico Investigation and Identification of Bioactive Compounds from Medicinal Plants as Potential Inhibitors against SARS-CoV-2 Cellular Entry 


Chukwuebuka Egbuna chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom).. Chukwuebuka Egbuna is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has been engaged in a number of roles at New Divine Favor Pharmaceutical Industry Limited, Akuzor Nkpor, Anambra State, Nigeria, and Chukwuemeka Odumegwu Ojukwu University (COOU) in Nigeria. Egbuna has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited over 20 books with Elsevier, Springer, Wiley and Taylor & Francis. His most recent book is his 3 volume book on Coronavirus Drug Discovery published by Elsevier. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services. He is a reviewer and editorial board member of various journals. His primary research interests cut across biochemistry, phytochemistry, pharmacology, nutrition and toxicology, food and medicinal chemistry, and analytical biochemistry.